Volume 7.13 | Apr 15

Prostate Cell News 7.13 April 15, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer
The authors identified a group of androgen receptor-regulated enhancer RNAs that are upregulated in castration-resistant prostate cancer cells, patient-derived xenografts, and patient tissues. [Cell Rep]
Full Article | Graphical Abstract
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

Targeting of Short TRPM8 Isoforms Induces 4TM-TRPM8-Dependent Apoptosis in Prostate Cancer Cells
Researchers identified sM8s as putative regulator of prostate cancer cell death. Suppression of sM8 isoforms was found to induce concomitantly ER stress, oxidative stress, p21 expression and apoptosis in human epithelial prostate cancer cells. [Oncotarget] Full Article

Regulation of Tumor Suppressor EAF2 Polyubiquitination by ELL1 and SIAH2 in Prostate Cancer Cells
Investigators showed that RNA Polymerase II Elongation Factor (ELL)-associated factor 2 (EAF2) can be polyubiquitinated and its degradation blocked by proteasome inhibitor. Co-immunoprecipitation detected EAF2 binding to SIAH2, an E3 ligase, and SIAH2 overexpression enhanced polyubiquitination of EAF2. [Oncotarget] Full Article

Prostate-Specific Membrane Antigen-Targeted Liposomes Specifically Deliver the Zn Chelator TPEN Inducing Oxidative Stress in Prostate Cancer Cells
Scientists evaluated the potential use of zinc chelation for prostate cancer therapy using a new liposomal formulation of the zinc chelator, N,N,N’,N’-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN). [Nanomedicine (Lond)] Abstract

Oxidative Phosphorylation and Mitochondrial Function Differ between Human Prostate Tissue and Cultured Cells
Researchers showed that mechanical treatment without chemical permeabilization agents or sample processing constitutes a reliable preparation method for oxidative phosphorylation analysis in small amounts of prostatic tissue typically obtained by prostate biopsy. [FEBS J] Abstract

17β-Hydroxy-18-Acetoxywithanolides from Aeroponically Grown Physalis crassifolia and Their Potent and Selective Cytotoxicity for Prostate Cancer Cells
Withanolides 1-11 and 16 were evaluated for their potential anticancer activity using five tumor cell lines. Of these, the 17β-hydroxy-18-acetoxywithanolides 1, 2, 6, 7, and 16 showed potent antiproliferative activity, with some having selectivity for prostate adenocarcinoma compared to the breast adenocarcinoma, non-small-cell lung cancer, and CNS glioma cell lines used. [J Nat Prod] Abstract | Graphical Abstract

P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate
Investigators studied the effects of p21-activated kinase inhibitors (FRAX486, IPA3) in hyperplastic human prostate tissues, and in stromal cells (WPMY-1). In hyperplastic prostate tissues, PAK1, -2, -4, and -6 may be constitutively expressed in catecholaminergic neurons, while PAK1 was detected in smooth muscle and WPMY-1 cells. [PLoS One] Full Article


Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: a Multicenter Retrospective Analysis
Researchers evaluated response and tolerability of a single dose of 177Lutetium-prostate specific membrane antigen-617 (Lu-PSMA) in a large cohort of patients with metastatic castration resistant prostate cancer. [J Nucl Med] Abstract

Third-Line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
Scientists evaluated the activity of third-line enzalutamide in men with castrate-resistant prostate cancer after docetaxel and abiraterone. [Anticancer Res] Abstract

Enter for a chance to win ISSCR 2016 Travel Support Award to San Francisco!
Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
The clinical utility of taxane-based drug formulations in castration-resistant prostate cancer is severely limited by acquired chemotherapy resistance, dose-limiting toxicities, and nonresponders. The authors highlight the strategies that aim to overcome these limitations, such as bypassing therapy resistance, targeted drug delivery, and adequate prediction of therapy response. [Trends Pharmacol Sci] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Tokai Announces Presentations on Galeterone
Tokai Pharmaceuticals Inc. announced that two presentations on galeterone will be made during poster sessions. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistance prostate cancer. [Press release from Tokai Pharmaceuticals Inc. discussing research to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, New Orleans] Press Release

Asana BioSciences, LLC to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program
Asana BioSciences, LLC announced that it will present preclinical data regarding its product candidate, ASN007A. [Press release from Asana BioSciences, LLC discussing research to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, New Orleans] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
Proton Therapy Treatment Center Agreement Reached
Delray Medical Center has reached agreement with Proton International to build a one-room proton therapy treatment center serving the South Florida corridor. Proton therapy, a form of radiation therapy, is a highly precise and effective treatment for many cancer tumors but without many of the side effects that often accompany treatment. [Proton International] Press Release

University of Pennsylvania to Join First-of-Its-Kind Research Collaboration to Fight Cancer with New Immunotherapies
The University of Pennsylvania has joined an unprecedented cancer research effort, the Parker Institute for Cancer Immunotherapy, which unites six of the nation’s top medical schools and cancer centers around a shared aim of accelerating breakthrough immunotherapy research that will turn more cancers into a curable disease. The venture is backed by a $250 million gift from the Parker Foundation, making it the largest single contribution ever made to the field of immunotherapy. [University of Pennsylvania] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 24th Biennial European Association for Cancer Research (EACR) Congress
July 9-12, 2016
Manchester, United Kingdom

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Epithelial Homeostasis and Carcinogenesis (Baylor College of Medicine)

PhD Studentship – Vesicles to Target Prostate Cancer Metastasis (University of East Anglia)

PhD Studentship – Various Projects (Cancer Research UK Manchester Institute)

Lead Scientist – Prostate Cancer (Memorial Sloan Kettering Cancer Center)

Postdoctoral Fellowship – Castration Resistant Prostate Cancer (University of Florida)

PhD Studentship – Wnt Signaling in Stem Cells and Cancer (German Cancer Research Center)

Postdoctoral Fellowship – Prostate and Breast Cancer Molecular Mechanisms (Feinberg School of Medicine)

Tenure Track Faculty Positions – Various Methods in Cancer Biology (Paul L. Foster School of Medicine)

Research Group Leader – Stress Regulated Processes During Oncogenesis (INSERM)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us